: Nucleoside & Guanosine Reverse Transcriptase Inhibitor. Lamivudine 300 mg, Abacavir 600 mg. TABS.:30. The recomm. dosage for adult.& child. over the age of 12 wt. at least 40 kg, is one tab., once dly. See lit.
Indicated in antiretrovir. comb. ther. for the tmt. of (HIV) infect. in adult., adolesc. and child. weigh. at least 25 kg.
C/I: Hypersens.
Cannabinoids, Specific Immunoglobulin. Palvizumab 50 mg, 100 mg. VIAL(PWDR) + DILUENT: 1 X 50 mg+ 4 ml
diluent, 100 mg + 10 ml diluent.
15 mg/kg by I.M. inject. 1 x mthly
during course of RSV season. See lit.
Preven. of serious lower resp. tract dis.
requir. hospitalis. caused by RSV in child.
at high risk for RSV dis.:
Child. born at 35 wks. of gestation or less
and less than 6 mths. of age at the onset
of the RSV season. Child. less than 2 yrs. of age and requir.
tmt. for bronchopulm. dysplasia within
the last 6 mths.
Children less than 2 yrs. of age and with
haemodyn. signif.congen. heart dis.
C/I: Hypersens. to palvizumab or any
compon. of formula, or other humanized
monoclonal antibodies.
Bevacizumab 25 mg/ml. VIALS: 1 x 100 mg/4 ml; 1 x 400 mg/16ml
Metastatic carcinoma of the colon or rectum (mCRC)
5 mg/kg or 10 mg/kg once every 2 weeks or 7.5 mg/kg or 15 mg/kg once every 3 weeks. until progression of dis. or unacceptable tox.
Metastatic breast cancer (mBC)
10 mg/kg once every 2 weeks or 15 mg/kg once every 3 weeks until progression of dis. or unacceptable tox.
Non-small cell lung cancer (NSCLC)
First-line tmt. of non-squamous NSCLC in combin. with platinum-based chemother.:
in addition to platinum-based chemother. for up to 6 cycles of tmt. followed by this drug as a sgle. agent until dis. progress. 7.5 mg/kg or 15 mg/kg once every 3 weeks. Clinical benefit in NSCLC pts. has been demonstrated with both 7.5 mg/kg and 15 mg/kg doses. until progress. of dis. or unacceptable tox.
First-line tmt. of non-squamous NSCLC with EGFR activating mutations in combin. with erlotinib:
EGFR mutation testing should be performed prior to init. of tmt with the combin. of this drug and erlotinib. It is important that a well-validated and robust methodology is chosen to avoid false neg. or false posit. determination.
15 mg/kg once every 3 weeks until dis. progress.
Advanced and/or metastatic renal cell cancer (mRCC)
10 mg/kg once every 2 weeks until progress. of the dis. or unacceptable tox.
Malignant Glioma (WHO Grade IV) - Glioblastoma
10 mg/kg once every 2 weeks or 15 mg/kg once every 3 weeks. until progress. of dis. or unacceptable tox.
Epithelial ovarian, fallopian tube and primary peritoneal cancer
Front-line tmt.:
in addition to carboplatin and paclitaxel for up to 6 cycles of tmt. followed by cont. use of this drug as sgle. agent until dis. progress or for a max. of 15 months or until unacceptable tox., whichever occurs earlier. Dose of this prod. is 15 mg/kg once every 3 weeks.
Tmt. of platinum-sensitive recurrent dis.
in combin. with carboplatin and gemcitabine for 6 cycles and up to 10 cycles followed by cont. use of this drug as sgle. agent until dis. progress. Dose is 15 mg/kg once every 3 weeks.
Tmt. of platinum-resistant recurrent dis.
In combin. with one of the following – paclitaxel, topotecan (given weekly) or pegylated liposomal doxorubicin. The dose of this drug is 10 mg/kg once every 2 weeks. When admin. in comb. with topotecan (on days 1-5, every 3 weeks), the dose of this drug is 15 mg/kg g once every 3 weeks. until dis. progress. or unacceptable tox.
Cervical Cancer
in comb. with one of the following chemother. regimens: paclitaxel and cisplatin or paclitaxel and topotecan. The dose of this drug is 15 mg/kg once every 3 weeks. until progress. of dis. or until unacceptable tox.
In comb. with fluoropyrimidine-based chemother -tmt. of pts. with metastatic carcinoma of the colon or rectum.
In comb. with paclitaxel - first-line tmt. of adlt. pts. with metastatic breast cancer.
In addition to platinum-based chemother- first-line tmt. of pts. with unresectable adv. metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.
In comb. with erlotinib -first-line tmt of adlt. pts. with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations.
In combin. with interferon alfa-2a - first line tmt. of pts. with adv. and/or metastatic renal cell cancer.
As a single agent, - tmt. of glioblastoma in patients with progress. dis. following prior ther.
In combin. with carboplatin and paclitaxel - front-line tmt. of advanced ([FIGO] stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are at high risk for recurrence (residual disease after debulking).
In comb. with carboplatin and gemcitabine, - tmt. of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior ther. with bevacizumab or other VEGF inhibit. or VEGF receptor-targeted agents.
In combin. with paclitaxel, topotecan, or pegylated liposomal doxorubicin – ttmt. of adult pts. with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemother. regimens and who have not received prior ther. with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.
In combinat. with paclitaxel and cisplatin or, paclitaxel and topotecan, - tmt. of pts. with persistent, recurrent, or metastatic carcinoma of the cervix
C/I: Hypersens
Hypersens. to Chinese Hamster Ovary (CHO) cell prod. or other recomb. human or humanised antibodies. Pregn.
Atypical Antipsychotic. Aripiprazole (as monohydrate) 300 mg, 400 mg. PRE-FILLED SYR. (pwdr.+ solvent for prolong. -release susp.): 1,3. Recom. init. & mainten. dose: 400 mg. once mnthly. as a single inj. (no sooner than 26 d after the previous inj.). After the 1st inj., tmt. with 10 mg-20 mg oral aripiprazole should be cont. for 14 consec. days to maintain therapeutic aripiprazole concent. during init. of ther. See lit.
Maintenan. tmt. of schizophrenia in adult pts. stabilised with oral aripiprazole.
C/I: Hypersens.
Alkylating Agent (platinum analog). Cisplatin 1 mg/ml. VIALS: 1 x 100 ml, 50 ml. See lit.
Palliative in add. to other modalities
in
tmt. metastat. testic. and ovar. cancer,
advanced bladder cancer.
Androgen Biosynthesis Inhibitor. Abiraterone Acetate 250 mg , 500 mg. TABS.: 250 mg x 120 , 500 mg x 60.
Intended for male pts. only. 1,000 mg (4×250mg tabs. or 2x500mg tabs.) once dly.
1. in combin. with prednisone for metast. castrat.-resist. prostate cancer.
2. For newly diag. high risk metast. hne. sensit. prostate cancer (mHSPC) in adlt. men in combinat. with androgen depriv. ther.(ADT) and in combin. with prednisone.
C/I: Hypersens./ by pregn. females or who may be potent. pregn../sev. hepat. impairm./ in combin. with Ra-223 if given with prednisone.
